STOCK TITAN

Revvity, Inc. - $RVTY STOCK NEWS

Welcome to our dedicated page for Revvity news (Ticker: $RVTY), a resource for investors and traders seeking the latest updates and insights on Revvity stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Revvity's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Revvity's position in the market.

News
Rhea-AI Summary
Revvity, Inc. unveils its inaugural 2023 ESG Report, highlighting its commitment to sustainability and transparency. Key goals include reducing greenhouse gas emissions by 50% by 2033, achieving net carbon neutrality by 2040, and maintaining greater than 40% female representation in leadership positions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
none
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) to release Q3 2023 financial results on October 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
-
Rhea-AI Summary
Revvity launches Pin-point base editing reagents, providing access to advanced gene editing technique. Can enhance drug development and streamline cell therapy research. Pin-point platform used in clinical settings. Reagents include mRNAs for nCas9 and rat APOBEC, as well as three guide RNAs. Revvity aims to democratize access to base editing. Entered non-exclusive license agreement with AstraZeneca.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
none
Rhea-AI Summary
Revvity debuts enhanced imaging portfolio with new systems, including IVIS Spectrum 2, IVIS SpectrumCT 2, Quantum GX3 microCT, and Vega ultrasound system
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.12%
Tags
none
-
Rhea-AI Summary
Revvity, Inc. (NYSE: RVTY) to present at upcoming healthcare conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.99%
Tags
conferences
-
Rhea-AI Summary
Revvity, Inc. reports Q2 2023 financial results with revenue of $709 million and GAAP EPS of $0.28. Updates full year 2023 guidance with total revenue forecast of $2.80-$2.85 billion and adjusted EPS of $4.70-$4.90.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
dividends
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.41%
Tags
Rhea-AI Summary
Honeycomb Biotechnologies and Revvity launch new solutions for single cell biology, including the HIVE CLX Single-Cell RNAseq Solution and BeeNetPLUS analysis workflow. The HIVE CLX solution offers higher density single cell capture with integrated sample storage, making it easier to study rare and fragile cell types. It also supports studies in innate immunology, infectious diseases, and clinical research. Honeycomb has also released the BeeNetPLUS cloud-based analysis workflow, and researchers in the US can take advantage of the HIVE CLX Service offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.1%
Tags
none
Revvity, Inc.

NYSE:RVTY

RVTY Rankings

RVTY Stock Data

13.54B
111.70M
0.28%
88.02%
2.18%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
WALTHAM

About RVTY

as a leader focused on improving human and environmental health, we are helping scientists, clinicians, and government agencies discover more effective diagnostics and therapies, and making sure that the food we eat and the air we breathe are safe from contaminants. environmental health overview at perkinelmer, we’re taking action to ensure the quality of our environment. the ability to rapidly detect known and unknown contaminants in our food, water and air, or to monitor their quality consistently, is an important part of maintaining a healthy environment. our systems and services help scientists understand all of these complexities and ensure compliance. from food safety to air & water quality, perkinelmer transforms information into results that improve our health and safety today and our world tomorrow. human health overview perkinelmer creates life science research and diagnostic instrumentation as well as informatics and diagnostic lab services—all to fight illness proacti